Nutex Health 2025 Q2 Earnings Surges 436.3% in Net Income Despite EPS Loss

Nutex Health (NUTX) reported Q2 2025 earnings on Nov 18, 2025, surpassing expectations with a 220.7% revenue surge to $244 million and a 436.3% net income jump to $16.14 million. The stock repurchase program and arbitration integration highlight strategic confidence, though EPS widened to -$2.95.

Revenue

Nutex Health’s total revenue surged 220.7% year-over-year to $243.99 million in Q2 2025, driven by robust performance across its Hospital division, which contributed $236.30 million. The Population Health Management division added $7.68 million, while the Real Estate division reported $0. This 220.7% increase underscores the company’s strong operational execution and market expansion.

Earnings/Net Income

Despite a widened loss per share to -$2.95 from -$0.07, Nutex Health’s net income soared 436.3% to $16.14 million in Q2 2025. This marks a record high for fiscal Q2 net income in six years, reflecting improved profitability despite one-time stock-based compensation expenses. The earnings highlight the company’s ability to balance high-growth investments with core operational gains.

Post-Earnings Price Action Review

The strategy of buying Nutex Health shares on revenue raise announcements and holding for 30 days showed mixed results. Over three years, it yielded an average 10% quarterly return but faced volatility, with quarterly swings from -20% to +40%. Cumulative returns reached 30%, yet two quarters saw losses below -10%, underscoring the high-risk nature. Healthcare sector dynamics, regulatory shifts, and market sentiment further amplified uncertainty. Investors must weigh these risks against potential rewards.

CEO Commentary

Tom Vo, CEO, emphasized 217.5% revenue growth, $144.4 million Adjusted EBITDA (up 2144.2% YoY), and a $96.7 million cash balance. He highlighted the arbitration process’s integration into revenue cycle management and the $25 million share repurchase program as confidence in long-term value.

Guidance

Nutex Health announced a $25 million share repurchase program over six months, aiming to offset dilution from stock compensation for under-construction hospitals. The program remains subject to market conditions and management discretion, with no obligation to execute the full amount.

Additional News

1. Restated 2024 Financials: Nutex Health restated 2024 financials, correcting $16.4 million in stock-based compensation classifications. Total revenue rose 93.8% to $479.9 million, and net income surged to $52.1 million.

2. Share Repurchase Program: The $25 million repurchase plan, announced on Aug 14, 2025, aims to boost EPS and shareholder returns while countering dilution.

3. Q2 2025 Loss Report: The company reported a Q2 loss of -$17.7 million, driven by $78.7 million in stock-based compensation for under-construction hospitals.

Image

Key Financials

• Revenue: $243.99M (+220.7% YoY)

• Net Income: $16.14M (+436.3% YoY)

• EPS: -$2.95 (vs. -$0.07 YoY)

• Adjusted EBITDA: $144.4M (+2144.2% YoY)

• Cash Balance: $96.7M (6M)